

May 2022

## We create value in Life Science















## MedCap | An active investor in Life Science companies

#### **MedTech Business Area**











#### **Specialty Pharma Business Area**



#### Sales by Segment (MSEK)



#### Geographies




#### **Employees**

363

Listed on Stockholm Nasdaq Mid Cap



## Sales and EBITDA rolling 12 months by quarter







## Highlights Q1

- Sales growth by 18%
- EBITDA increased by 39%
- All companies in both business areas, MedTech and Specialty Pharma, contributed to growth
- Profitability driven by volume growth
- Price increases partially offset
- Long lead-times drive inventory increase but no significant impact on sales
- Strong margin (21% EBITDA-margin (18%))
- Strong balance sheet (ND/EBITDA: -0.4)

Jy y		
174/7	Q1	R12
Net Sales growth	+18%	+15%
EBITDA growth	+39%	+31%
EBITDA- margin	21%	23%
oras /		





# Contributing to an equal society; products that leads to better health and inclusion in society

2021 Highlights

Tender renewals

Product launches

## Our areas of expertise

























## Streamlined workflow with digital ECG

2021 Highlights


Product launches

Broader 'go to market'

### A COMPLETE DIGITAL SOLUTION WITHIN ECG



ECG SYSTEMS



ECG MANAGEMENT SYSTEM



VACUUM SYSTEM & ELECTRODES



## **I∩D**∂**©** | Packaging Solutions

#### **PROBIOTICS**

Inpac Probiotics is a Nordic-based company with experience and expertise in packaging pharmaceuticals and probiotics primarily for the Nordic and European markets. With our hitech and well-equipped facility in Sweden we can provide all the services you would expect from a packaging partner. We are big enough to take on important, business critical projects, yet small enough never to lose focus on our customers. What makes us unique as a partner are our three driving forces, which profoundly shape our company and our way of working: Creativity, Passion and Precision.



#### NUTRIENTS

We are a manufacturer and supplier of dietary health and nutritional supplements offering Contract Manufacturing, Private Label, Bulk Raw Material Supplies, Ingredient and Formula Consulting Services for customers worldwide. We offer a complete line of the highest quality Amino acids, Proteins, Nutraceuticals, Vitamins, Minerals, Herbs and Specialty Products



Nutrition Growth

Profitability growth





## MULTIPLY | Carbon Fibre Manufacturer for Medical

2021 Highlights

New OEM customer

Setting up for Growth

#### OEM Partnerships + Engineering & Manufacturing Expertise



New Facility to Improve Operations and Capacity







#### 2021 Highlights

Product launches

Outlicensing


#### Specialty Pharma

- Business Development
- Registered Pharmaceuticals (own and partner products)
- Non-Licensed pharmaceuticals
- Extemporaneous formulations

## Development & Manufacturing - CDMO

- Laboratory Services
- Development Services
- Contract Manufacturing (sterile and non-sterile liquids)
- Finished drugs

#### Building the registered specialty pharma portfolio





## **Financial Targets**





## Investment strategy

#### Investment criteria

#### What we look for in a company

**Life Science** MedTech, Specialty Pharma Small and mid-sized (<25 mEUR)

**Majority** Ownership **Long-term**No exit horizon

Europe HQ in Northern Europe; Add-ons globally

**Targeting** 5 – 10 core investments





### Why invest in MedCap?

1

#### Important Industry

Life Science industry improves quality of life

MedCap's portfolio companies contributes to inclusion, care and healthcare

We strive to operate sustainable and work towards UN's sustainable development goals

2

#### Profitable Growth

Annual growth of 12% over the last 5 years

Annual EBITDA growth of 39% over the last 5 years

Objective to increase EBITDA by more than 15% per year

Objective to grow significantly; both organic and acquisitions

3

#### Proven Model

Decentralized model – customer oriented responsibility and decisions making

Combination of entrepreneurial drive in smaller companies and the strength of a larger group

Long-term value creation

4

#### Large & Growing Market

Fragmented market – many small and medium sized life science companies in Europe

Growing market – healthcare investments and innovation drives growth

Many acquisition targets



### Thank You!

Q & A



Anders Dahlberg CEO anders.dahlberg@medcap.se +46 704 269 262



Kristina Ekblad CFO kristina.ekblad@medcap.se +46 703 322 167

